1. Background {#s0005}
=============

Infants with phenylketonuria (PKU) are treated with a low phenylalanine (Phe) diet supplemented with Phe-free L-amino acids (L-AA). In early infancy, either breast milk or a standard infant formula is given to supply Phe requirements. The volume of either milk is titrated to individual tolerance with the remaining nutritional requirements being provided by Phe-free L-AA infant formula \[[@bb0005]\], until the commencement of solid introduction (weaning).

The World Health Organization (WHO) and UK Scientific Advisory Board on Nutrition (2018) recommends that weaning should commence from 6 months of age (≈26 weeks) \[[@bb0010]\] as infants are usually developmentally ready to accept solids. Alternatively, the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) advocates weaning from 17 to 24 weeks \[[@bb0015]\]. In PKU, the definitive age for the inauguration of weaning remains undefined as infants have already been exposed to complementary feeds in the form of Phe-free L-AA infant formula. In addition, infants have extra stages in their feeding development that require consideration such as the introduction of a second stage protein substitute \[[@bb0020]\]. The weaning process may be prolonged as each feeding stage has to be directed by a dietitian/doctor before changes can occur in the feeding plan.

In 1999, a multicentre study from the UK and Australia (*n* = 13 centres) \[[@bb0025]\] reported that solids were usually introduced early (between 3 and 6 months), with low Phe solids such as fruit and vegetables being given first. Although this timing is different from weaning recommendations, few infants were breast fed in this study (28% of United Kingdom patients and 41% of Australia patients). In PKU, some infants may not be satiated with Phe-free L-AA infant formula and there is less flexibility in adjusting breast or standard infant formula volumes in response to appetite without adversely affecting metabolic control (unless a protein-free formula is also administered). Although in PKU there is no evidence to suggest that Phe-free L-AA infant formula impacts on appetite, non PKU studies have established that whole protein is more satiating than amino acid formula \[[@bb0030],[@bb0035]\].

Furthermore, some infants have poor acceptance of Phe-free L-AA infant formula and fail to drink the prescribed amounts, so they may be hungry, leaving little choice but to proceed with the introduction of solid foods to satisfy appetite.

It is almost 20 years since the first paper on multi-centre weaning practices was published in PKU \[[@bb0025]\]. Differences in the timing of solid food introduction, policies on allocation of dietary Phe, dosage and type of protein substitute prescribed at weaning may impact on future feeding development. Therefore, it is important to re-examine how dietary advice on weaning differs between professionals and compare this with weaning advice for the general population. We report the weaning practices of health professionals working with PKU across Europe.

2. Material and methods {#s0010}
=======================

A cross sectional, non-validated, survey monkey® questionnaire was sent to European IMD (Inherited Metabolic Disorders) health professionals (dietitians/nutritionists and medical doctors) who were either members of the *'Society for the Study of Inborn Errors of Metabolism'* (SSIEM) or who have participated in previous European surveys assessing dietary practices \[[@bb0040],[@bb0045]\]. The questionnaire was composed of 31 open, single and multiple-choice questions on infant feeding in PKU with 14 questions focused on weaning. Questions examined: weaning age; first weaning foods; age of introduction of Phe containing foods; method of allocating Phe into the diet; age of introduction of low protein milk, low protein bread and 'finger foods'; changes to protein substitute prescription during weaning and age of introduction of second stage protein substitute in the weaning period.

The questionnaire was written in English but linguistic support in Portuguese, French, Spanish and Italian was provided by the first author \[AP\] to clarify any queries. Only one answer per centre was accepted from health professionals and participants were instructed to answer each question according to their general clinical practice rather than for individual patient cases. The questions were devised to encompass all the possible/most common practices across different European countries. A pilot questionnaire was given to 20 dietitians who attended an International meeting. Because of this, changes were made to the questionnaire to improve clarity of questions if there was ambiguity with question structure.

The questionnaire responses were analysed according to the individual centres in addition to the geographical region of responding centres. Results were analysed in two parts: 1) early infant feeding and 2) weaning procedures. The results of the survey about early feeding practices has already been published \[[@bb0050]\].

3. Results {#s0015}
==========

3.1. Participants {#s0020}
-----------------

Ninety-five centres from 21 European countries responded to the questionnaire. Centres were grouped into the following geographical regions in order to analyse the results:•Southern Europe (*n* = 30 centres): Portugal (*n* = 7 centres), Italy (*n* = 6 centres), Spain (*n* = 9 centres), Greece (*n* = 2 centres) and Turkey (n = 6 centres);•Western Europe A (*n* = 16 centres): Belgium (n = 6 centres), France (*n* = 5 centres) and The Netherlands (n = 5 centres);•Western Europe B (*n* = 15 centres): Germany (*n* = 13 centres) and Austria (n = 2 centres);•Northern Europe (*n* = 24 centres): United Kingdom (*n* = 17 centres), Sweden (n = 3 centres), Norway (n = 1 centre), Denmark (n = 1 centre), Finland (n = 1 centre) and Ireland (n = 1 centre);•Eastern Europe (*n* = 10 centres): Latvia (n = 1 centre), Poland (n = 6 centres), Slovakia (n = 1 centre), Hungary (n = 1 centre) and Estonia (n = 1 centre).

3.2. Weaning commencement {#s0025}
-------------------------

In the participating centres, weaning commenced at age: \<17 weeks in 3% (n = 3/95), from 17 to 26 weeks in 85% (*n* = 81/95) and \> 26 weeks of age in 12% (*n* = 11/95). The main factors influencing solids commencement were infant\'s age (*n* = 85/95 centres) and infants showing an interest in food (*n* = 70/95). The first weaning foods suggested by centres were low Phe vegetables (59%, *n* = 56/95), low Phe fruits (34%, *n* = 32/95), low Phe cereal (6%, n = 6/95) and low protein *finger foods* \[1%, *n* = 1/95\].

Centres introduced Phe containing foods such as cereal, potato or yoghurt to replace Phe from breast milk or standard infant formula at infant age: \< 17 weeks in 1% (n = 1/95), from 17 to 26 weeks in 51% (*n* = 48/95) and \> 26 weeks in 48% (*n* = 46/95). Centres expressed a preference for either allocating Phe containing foods by an exchange system (52% of centres, *n* = 49/95) or calculating the Phe content of individual foods (48%, n = 46/95). Some centres commented how they choose a system according to the preference and ability of an individual family and so use both systems in their centres.

When centres used exchange systems to allocate Phe, different Phe amounts were used to define one Phe exchange: between 10 and 25 mg of Phe (19% of centres, *n* = 18/95), 50 mg of Phe (31%, *n* = 29/95), or an unspecified amount (11%, *n* = 10/95), with some centres using more than one exchange system, which was determined by the Phe concentration of foods.

Low protein milks (e.g. ProZero®, Sno-Pro® and Dalia®) given as a drink or added to foods such as low protein cereal/desserts were introduced: \<6 months of age in 1% (n = 1/95) of centres, 6--8 months in 19% (n = 18/95), 9--12 months in 23% (*n* = 22/95) and \> 12 months in 57% (*n* = 54/95).

Low protein bread was introduced by centres at: \<6 months of age in 3% (*n* = 3/95), between 6 and 8 months in 36% (*n* = 34/95), 9--12 months, 44% (*n* = 42/95) and \> 12 months in 17% (*n* = 16/95).

3.3. Weaning process: L-AA supplement {#s0030}
-------------------------------------

A second stage L-AA supplement containing a higher Phe-free amino acid concentration than Phe-free infant formula was introduced by centres at the following infant ages: \<26 weeks, 9% (*n* = 9/95); 26--36 weeks, 41% (*n* = 39/95); 37--52 weeks, 13% (*n* = 12/95); and \> 1y, 37% (*n* = 35/95) \[[Fig. 1](#f0005){ref-type="fig"}\].Fig. 1The age of introduction of a second stage protein substitute in each age category by centres in different geographical regions.Fig. 1

Over half of the centres (53%, *n* = 50/95) recommended that a second stage L-AA supplement was administered as a semi-solid (paste/gel), 18% (*n* = 17/95) as a concentrated drink, 19% (n = 18/95) as a non-concentrated drink and 11% (n = 10/95) gave a second stage protein substitute via a different, non-specified method.

4. Discussion {#s0035}
=============

This paper reports European health professionals\' infant weaning practices in PKU. The initial approaches to weaning are very similar, with the majority of centres introducing solids between 17 and 26 weeks of age commencing with low Phe fruit and vegetables. There were different systems to allocate calculated Phe containing foods into the diet, and although over half of the centres introduced a more concentrated source of protein substitute from 6 months, centres from Southern Europe and Western Europe A (Portugal, Spain, Greece, Turkey, Belgium, France and The Netherlands) delaying its introduction until after the first year of age.

There is evidence in non-PKU healthy infants that early solid introduction reduces breast milk volume and deferring weaning until 6 months of age is not associated with lower acceptance of solid foods \[[@bb0010]\]. However, in PKU, the age of weaning may affect the acceptance of a second stage protein substitute and any rejection of protein substitute is associated with worsening of blood Phe control. Although the ideal time to introduce solids in infant's with PKU is not established, as second stage protein substitute is often added in parallel with low Phe food introduction, later food introduction may alter acceptance of second stage protein substitute \[[@bb0055]\].

While dietary Phe (to replace Phe from breast milk or infant formula) was added either in the form of an exchange system or by calculating Phe intake of most foods, there was suggestion that dietary practices were changing and were more flexible. Some centres introduced lower Phe containing fruits and vegetables at weaning without calculation which should benefit infants by improving infant exposure to a wider range of tastes and textures. Over recent years the system of allocating dietary Phe has provoked much discussion but increasing evidence is supporting a 'simple' diet in PKU \[[@bb0060], [@bb0065], [@bb0070]\] and there is no data to suggest that this is associated with loss of blood Phe control. The European PKU Guidelines \[[@bb0075]\] supported a system where fruits and vegetables containing Phe ≤75 mg/100 g are considered as 'exchange free' foods and thereby permitted without measurement \[[@bb0080], [@bb0085], [@bb0090]\]. There is also evidence suggesting that there may be some over restriction of prescribed dietary Phe below individual tolerance \[[@bb0095]\]. European countries using Phe exchange systems do not seem to have worse metabolic control than centres that estimate all Phe intake \[[@bb0100]\]. In addition, Phe food analysis is associated with inaccuracy and published figures of the Phe content of food are inconsistent \[[@bb0105]\]. Furthermore, different definitions for the amount of Phe in one exchange were used in our survey and future PKU guidelines should aim to harmonize practice. It is essential patients receive standard information from health professionals, especially when so much information is accessible through the internet and social media.

There is already a high burden for caregivers of children with PKU with the extra time associated with managing the disorder \[[@bb0110],[@bb0115]\], which may lead to caregivers reducing working hours or even leaving their jobs \[[@bb0115]\]. It has been reported in a UK survey that a median of almost 2 h per week was spent weighing foods \[[@bb0115]\] using an exchange system. It is likely that even more time will be necessary if Phe intake from almost all food is measured, resulting in additional anxiety, although it has been documented that many families do not sustain the practice of weighing foods beyond early childhood \[[@bb0120]\].

This survey indicated low use of low protein special foods during weaning. Generally, Northern European centres introduced these foods earlier than other regions, which may be influenced by low protein food availability and national prescription systems. Introduction of low protein foods in the first year might be associated with better acceptance, but if caregivers must pay for them, they may consider that high waste (common during weaning) does not justify their expense. In addition, caregivers are at an early stage in attaining their low protein cooking skills, which may also limit infant exposure to low protein special products. Delayed introduction and lack of exposure to their textures or taste may lead to rejection but this needs further exploration in PKU.

Second stage protein substitutes were recommended in various forms according to geographical region. This could be related to availability of protein substitutes in different countries. Almost two thirds of centres introduced a second, more concentrated source of Phe-free L-AA supplement by the time infants were aged one year. The majority of centres from Southern Europe delayed its introduction until after the first year of age but overall there was a change in practice from an earlier multicentre study \[[@bb0025]\], which was associated with an even later introduction of a concentrated protein substitute. A study examining feeding problems in PKU, showed that high volumes of Phe-free liquid L-AA supplement (required if a concentrated protein substitute is not introduced during weaning) was associated with crying, screaming, gagging and protein substitute rejection \[[@bb0125],[@bb0130]\]. Practice may be to add second stage protein substitute to a feeding bottle, and although this may help to conceal its bitter taste and distinct smell, it does not support good dental health or overall feeding development.

In a retrospective, longitudinal review over 15 years, Evans et al. \[[@bb0055]\] showed that a semi-solid/spoonable L-AA supplement given from 20 weeks was well tolerated, and any feeding problems encountered were comparable to the problems observed in children without PKU. In this study, there was a trend for children weaned before 17 weeks of age and those commencing weaning protein substitute late (\>26 weeks of age) to refuse a second stage, spoonable L-AA supplement at some point. In our survey, only 9% of centres commenced a second stage weaning L-AA supplement before 26 weeks and 37% started only after the first year of age. Prospective longitudinal studies are required to compare the effect of earlier and late introduction of second stage protein substitute with longer-term acceptance of L-AA supplements in PKU.

This study had several limitations. It was a cross-sectional study rather than prospective. The questionnaire was non-validated although a pilot questionnaire was tested. Data was collected about general health professional practice rather than individual prescriptions. Therefore, this survey did not collect data about individual Phe tolerance or blood Phe control. Only one questionnaire was completed by each PKU centre and it is possible that different professionals may have had different approaches within the same centre.

5. Conclusions {#s0040}
==============

Weaning strategies vary widely according to different European regions. There is very little data about the definitive weaning process in PKU and this survey gives useful information on how different health professionals in treatment centres across Europe manage PKU. There is also suggestion that weaning practices have changed compared with an earlier survey. No reports are available assessing how different strategies may influence adherence to the PKU diet and acceptance of Phe-free L-AA supplement during childhood and later in life, so prospective long-term studies are important. It is essential to define the most acceptable weaning strategy for infants associated with the least caregiver burden and the best long term outcome in PKU.
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